Real‐world comparison of routine and companion diagnostic mismatch repair immunohistochemistry in a large Chinese pan‐tumour cohort
Histopathology · 19.11.2026
DOI: 10.1111/his.70315 ↗Kurz gefasst
Fachartikel in der Zeitschrift Histopathology, online erschienen am 19.11.2026. Verfasst von Shumei Yan und 6 weiteren Autor:innen. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aims
DNA mismatch repair (MMR) immunohistochemistry (IHC) is widely used for Lynch syndrome screening and selection of patients for immune checkpoint inhibitor (ICI) therapy. Standardized companion diagnostic (CDx) testing and interpretation frameworks support consistent patient classification. We evaluated routine clinical‐record MMR IHC results against the Food and Drug Administration‐approved CDx, VENTANA MMR RxDx Panel (Roche Diagnostics), and examined focal staining and reduced‐protein testing strategies. Methods and results This retrospective multicentre study included 1443 resection specimens from five hospitals in China: colorectal carcinoma (CRC; n = 402), endometrial carcinoma (EC; n = 413), gastric carcinoma (GC; n = 367) and other solid tumours ( n = 261). Concordance between historical clinical‐record MMR status and the CDx classification varied by tumour type. The highest agreement was observed in CRC and GC, whereas EC and the heterogeneous other‐tumour subgroup showed the lowest positive per cent agreement (95.81%) and the lowest negative per cent agreement (92.98%), respectively. Third‐panel assessment of 34 discordant cases supported the VENTANA classification in 31 cases, while the three remaining cases were unresolved without orthogonal molecular testing. Subclonal loss was identified in 74 of 525 dMMR cases (14.1%; most in MSH6 and MLH1), highlighting interpretative complexity beyond a binary framework. Reduced two‐protein testing, although operationally attractive, may miss clinically meaningful dMMR cases: the best‐performing PMS2/MSH6 combination was estimated to miss 33 dMMR cases when assessed against the VENTANA four‐protein classification.
Conclusions
These findings support full‐panel MMR assessment and adherence to CDx‐specific interpretation guidance to improve confidence in patient selection for ICI therapy.
Zitieren
APA
Yan, S., Kuang, D., Zhang, Y., Liu, Q., Zou, H., Wang, G., & Yun, J. (2026). Real‐world comparison of routine and companion diagnostic mismatch repair immunohistochemistry in a large Chinese pan‐tumour cohort. Histopathology. https://doi.org/10.1111/his.70315
Vancouver
Yan S, Kuang D, Zhang Y, Liu Q, Zou H, Wang G, et al. Real‐world comparison of routine and companion diagnostic mismatch repair immunohistochemistry in a large Chinese pan‐tumour cohort. Histopathology. 2026. doi:10.1111/his.70315
BibTeX
@article{Yan2026,
author = {Yan, Shumei and Kuang, Dong and Zhang, Yong and Liu, Qiang and Zou, Hong and Wang, Guoping and Yun, Jing‐Ping},
title = {Real‐world comparison of routine and companion diagnostic mismatch repair immunohistochemistry in a large Chinese pan‐tumour cohort},
journal = {Histopathology},
year = {2026},
doi = {10.1111/his.70315}
}
EUVIMED